Fresenius Kabi Oncology Ltd. - Research Center
FKONCO Group (B) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Dec' 13 | Sep' 13 | Jun' 13 | Mar' 13 | Dec' 12 | |
|---|---|---|---|---|---|
| Sales | 84.66 | 96.15 | 126.87 | 93.24 | 205.04 |
| Operating profit | -36.72 | -28.88 | 8.48 | 11.35 | 61.31 |
| Interest | 9.94 | 7.32 | -4.68 | -2.07 | -7.73 |
| Gross profit | -40.46 | -36.20 | 14.01 | 14.24 | 69.03 |
| EPS (Rs) | -4.02 | -2.83 | 0.30 | -0.49 | 3.06 |
Quarterly
results in details
| Dec' 13 | Sep' 13 | Jun' 13 | Mar' 13 | Dec' 12 | |
|---|---|---|---|---|---|
| Other income | 6.20 | - | 0.86 | 0.82 | - |
| Stock adjustment | -25.72 | -7.67 | 1.15 | -34.52 | 18.83 |
| Raw material | 53.88 | 35.05 | 35.59 | 51.55 | 29.05 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 20.29 | 20.37 | 15.21 | 17.41 | 17.16 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | 34.92 | 12.20 | 37.84 | 9.26 | 47.95 |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 38.01 | 65.08 | 28.60 | 38.19 | 30.75 |
| Provisions made | - | - | - | - | - |
| Depreciation | 8.34 | 7.53 | 6.91 | 6.53 | 6.69 |
| Taxation | 2.38 | 1.06 | 2.31 | 8.66 | 13.99 |
| Net profit / loss | -63.63 | -44.79 | 4.80 | -7.76 | 48.36 |
| Extra ordinary item | -12.44 | - | - | -6.81 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 15.82 | 15.82 | 15.82 | 15.82 | 15.82 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | 131.51 | 300.63 | 300.63 | 300.63 | 300.63 |
| Agg.of non promotoholding (%) | 8.31 | 19.00 | 19.00 | 19.00 | 19.00 |
| OPM (%) | -43.38 | -30.04 | 6.69 | 12.18 | 29.90 |
| GPM (%) | -44.53 | -37.64 | 10.97 | 15.14 | - |
| NPM (%) | -70.03 | -46.59 | 3.76 | -8.25 | - |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis